CompletedNot Applicable

Meningiomas and Treatment With CYPROTERONE ACETATE or Progestin

France110 participantsStarted 2019-02-25

Plain-language summary

Investigators observe an increase risk of meningioma in patient treated by CYPROTERONE ACETATE or other form of progestin. Investigatorsdiscribe caractéristics of meningioma and treatement of the patients follow up in CHRU of Brest

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * minimum 18 years * medical follow up in CHRU of Brest * treated by CYPROTERONE ACETATE and/or CHLORMADINONE ACETATE NOMEGESTROL ACETATE, PROGESTERONE , DYDROGESTERONE PROMEGESTONE , NORETHISTERONE, LEVONORGESTREL , oestroprogestogenic contraception * meningioma after treatement by progestin or CYPROTERONE ACETATE Exclusion Criteria: * history ofbreast cancer * history of cerebral radiotherapy * history of neurofibromatosis * meningioma before treatement by progestin or CYPROTERONE ACETATE * minor patient

What they're measuring

Diagnosis of meningiomas caracteristics

Timeframe: 12 months

Trial details

NCT IDNCT04109404

SponsorUniversity Hospital, Brest

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-06-01

View on ClinicalTrials.gov More Meningioma trials